Radiopharm Theranostics, Inc. (NASDAQ: RADX) is a clinical-stage radiopharmaceutical company focused on the development, manufacturing and commercialization of targeted radioligand therapies and diagnostic agents for oncology. By leveraging advances in nuclear medicine, the company seeks to create precision treatments that deliver therapeutic doses of radioisotopes directly to tumor cells while sparing healthy tissue. Its scientific platform encompasses both beta and alpha emitter modalities, enabling tailored approaches across a range of tumor types.
The company’s pipeline includes targeted therapies directed at prostate-specific membrane antigen (PSMA), as well as agents aimed at other solid tumors such as neuroendocrine and pancreatic cancers. Radiopharm Theranostics employs proprietary chemistry and conjugation techniques to attach clinically validated isotopes—such as lutetium-177 and actinium-225—to tumor-seeking ligands. Preclinical studies have demonstrated promising biodistribution and safety profiles, and the firm is actively enrolling patients in Phase 1/2 clinical trials in the United States.
Headquartered in Irvine, California, Radiopharm Theranostics maintains research laboratories and manufacturing capacity in key U.S. locations, complemented by strategic collaborations with contract development and manufacturing organizations (CDMOs) in Europe. These partnerships support the scalable production of short-lived isotopes and facilitate the company’s goal of establishing a robust supply network for investigational and commercial use. Radiopharm Theranostics also works closely with academic medical centers to advance clinical protocols and expand its data package.
Founded by a team of industry veterans with extensive backgrounds in nuclear medicine, pharmaceutical development and radiochemistry, Radiopharm Theranostics is led by a management group seasoned in regulatory strategy and global product launches. The executive team’s collective experience spans leading roles at both established biotech firms and major pharmaceutical companies. Together, they are positioning Radiopharm Theranostics to address unmet needs in cancer care through innovative, targeted radiopharmaceutical solutions.
AI Generated. May Contain Errors.
